Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma.
Zanolimumab (10 and 100 ng/mL) shows strong killing of the CD4+ T cells with a better effect to CD45RO+ subset than the CD45RA+ subset[1].
Zanolimumab (1-10000 ng/mL) Fc and dose-dependently down-regulates the level of CD4 from purified primary CD4+ T cells and SUP-T1 T cells[1].
Zanolimumab (1-10000 ng/mL) potently inhibits of TCR-stimulated T-cell proliferation both in tetanus toxin induced and anti-CD3 induced T-cell proliferation[1].
Zanolimumab (0-30 min) inhibits TCR signal transduction[1].
References:
[1]. Rider DA, et al. A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer Res. 2007 Oct 15;67(20):9945-53.